Kamiya H, Sono R, Kodama K, Kawasaki Y, Ido M, Sakatoku H, Kawamura Y, Shimizu S, Sakurai M
Jpn J Antibiot. 1985 Oct;38(10):2917-24.
Pharmacokinetic and clinical studies of ceftizoxime suppository (CZX-S) were performed in 10 children with the following results. CZX-S attained a peak serum concentration of 6.85 micrograms/ml 30 minutes after dosing with the drug 5.6 mg/kg (one suppository of CZX-S contains 250 mg of CZX in potency). The mean 6-hour urinary excretion rate in 4 children was 18.9%. The subjects consisted of 8 patients comprising 1 with pharyngitis, 3 with tonsillitis, 1 with gingivitis and 3 with urinary tract infection. The overall effect of CZX-S was "excellent" in 5 patients and "good" in 3, with an effectiveness rate of 100%. No side effects ascribable to CZX-S were encountered in any of the patients. A few patients complained of discomfort after the first or second insertion of the drug. However, the discharge of the suppository was as infrequent as 1.5% of the total 133 insertions. CZX-S is therefore well tolerated for clinical use in children. It is concluded that the unique suppository formulation of CZX-S is useful in the treatment of infections in children with heavy psychophysiologic disorders and in children who cannot take oral drugs because of severe vomiting.
对10名儿童进行了头孢唑肟栓剂（CZX-S）的药代动力学和临床研究，结果如下。以5.6mg/kg的剂量给药（一粒CZX-S栓剂含250mg有效成分的CZX）后30分钟，CZX-S的血清峰值浓度达到6.85微克/毫升。4名儿童6小时的平均尿排泄率为18.9%。受试者包括8名患者，其中咽炎1例，扁桃体炎3例，牙龈炎1例，尿路感染3例。CZX-S的总体疗效为5例“优”，3例“良”，有效率为100%。所有患者均未出现与CZX-S相关的副作用。少数患者在首次或第二次用药后抱怨有不适感。然而，栓剂排出的发生率仅为133次用药总数的1.5%。因此，CZX-S在儿童临床应用中耐受性良好。结论是，CZX-S独特的栓剂剂型对于治疗患有严重心理生理障碍的儿童以及因严重呕吐而无法口服药物的儿童的感染是有用的。
